Cybin Inc. Reports Q3 2025 Financial Results and Strategic Progress

Cybin, Inc. ( (CYBN) ) has released its Q3 earnings. Here is a breakdown of the information Cybin, Inc. presented to its investors.

Cybin Inc. is a clinical-stage neuropsychiatry company focused on developing innovative treatments for mental health conditions, with a particular emphasis on major depressive disorder and generalized anxiety disorder. In its latest earnings report, Cybin highlighted the launch of strategic clinical site partnerships to accelerate its PARADIGM Phase 3 program for CYB003, aimed at treating major depressive disorder. The company also announced upcoming milestones, including topline efficacy data from the CYB004 Phase 2 study and the initiation of pivotal studies for CYB003.

Key financial metrics from the third quarter of fiscal year 2025 include a cash balance of C$136.3 million and a net loss of C$10.5 million, a significant improvement from the previous year’s loss. Operating expenses increased to C$28.0 million, reflecting the company’s ongoing investment in research and development. Cybin also launched a new at-the-market equity program to raise up to US$100 million, aiming to support growth opportunities and working capital initiatives.

Strategically, Cybin is advancing its clinical programs with CYB003 receiving Breakthrough Therapy Designation from the FDA, which could potentially transform the treatment landscape for depression. The company is also progressing with its CYB004 program for generalized anxiety disorder, with results expected in the first half of 2025. Additionally, Cybin received its first U.S. patent for the CYB005 program, expanding its research pipeline.

Looking ahead, Cybin remains focused on executing its clinical programs and achieving key milestones in 2025. The company is poised to validate its promising Phase 2 data in larger patient populations and continues to explore innovative treatment options to address the unmet needs in mental healthcare.